<DOC>
	<DOCNO>NCT00110591</DOCNO>
	<brief_summary>The purpose study determine safety tolerability PRO 140 , investigational anti-HIV drug , administer via intravenous infusion . Study hypothesis : Single intravenous dos PRO 140 safely administer human result measurable concentration product serum .</brief_summary>
	<brief_title>Safety Tolerability PRO 140 HIV Uninfected Male Volunteers</brief_title>
	<detailed_description>PRO 140 man-made monoclonal antibody chemokine receptor CCR5 , serve co-receptor HIV . In numerous preclinical model HIV infection , PRO 140 broadly potently block CCR5-mediated HIV entry without block natural activity CCR5 . PRO 140 develop therapy HIV infected individual . The purpose study evaluate safety tolerability PRO 140 HIV uninfected male volunteer . The pharmacokinetics pharmacodynamics PRO 140 also assess study . Participants study randomly assign receive single dose one several possible dos PRO 140 placebo . Participants remain clinic observation evaluation 24 hour single-dose administration . Follow-up visit occur 2 , 3 , 5 , 7 , 10 , 14 , 28 , 42 , 60 day post-treatment . Physical exam , electrocardiogram ( ECGs ) , vital sign measurement , adverse event reporting , blood urine collection occur visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>HIV Antibodies</mesh_term>
	<mesh_term>PRO-140 monoclonal antibody</mesh_term>
	<criteria>Not 20 % 20 % ideal weight height estimate frame size Good health , clinically significant abnormal finding physical examination , medical history , laboratory test History clinically significant disease History clinically significant allergy , include drug allergy Participated another clinical trial within 3 month prior study entry HIV infect Hepatitis B C virus infect Active significant infection Prior exposure , allergy , know hypersensitivity PRO 140</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>